Latest Shionogi & Co Ltd (SGIOF) Headlines Dire
Post# of 3
DirectView Enters Into Preferred Security Provider Agreement with Legacy Construction Company of Colorado for their Existing and Future Marijuana Facility Construction Projects
PR Newswire - Wed Feb 26, 7:00AM CST
DirectView Holdings, Inc. (OTC: DIRV), a company focused on ownership and management of leading video and security technology companies, today announced that its wholly owned subsidiary DirectView Security has entered into a preferred provider agreement with Legacy Construction Company of Colorado, LLC ("Legacy").
Mycosis Fungoides - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4qbsj/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2013" report to their offering. 'Mycosis Fungoides - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. Scope - A snapshot of the global therapeutic scenario for Mycosis Fungoides. - A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mycosis Fungoides Overview Therapeutics Development Pipeline Products for Mycosis Fungoides - Overview Pipeline Products for Mycosis Fungoides - Comparative Analysis Mycosis Fungoides - Therapeutics under Development by Companies Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes Mycosis Fungoides - Pipeline Products Glance Late Stage Products Clinical Stage Products Mycosis Fungoides - Products under Development by Companies Mycosis Fungoides - Products under Investigation by Universities/Institutes Mycosis Fungoides - Companies Involved in Therapeutics Development Mycosis Fungoides - Therapeutics Assessment Drug Profiles interferon gamma-1a - Drug Profile brentuximab vedotin - Drug Profile brentuximab vedotin - Drug Profile methotrexate-AzoneTS - Drug Profile Genetically Modified T Cells-1138 - Drug Profile CIGB-128 - Drug Profile Mycosis Fungoides - Recent Pipeline Updates Mycosis Fungoides - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. Seattle Genetics, Inc. Echo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/x4..._fungoides About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hyperalgesia - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 07, 2:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/rrsm2z/hyperalgesia) has announced the addition of the "Hyperalgesia - Pipeline Review, H2 2013" report to their offering. 'Hyperalgesia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperalgesia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperalgesia. Scope - A snapshot of the global therapeutic scenario for Hyperalgesia. - A review of the Hyperalgesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hyperalgesia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Hyperalgesia Overview Therapeutics Development Pipeline Products for Hyperalgesia - Overview Pipeline Products for Hyperalgesia - Comparative Analysis Hyperalgesia - Therapeutics under Development by Companies Hyperalgesia - Therapeutics under Investigation by Universities/Institutes Hyperalgesia - Pipeline Products Glance Early Stage Products Hyperalgesia - Products under Development by Companies Hyperalgesia - Products under Investigation by Universities/Institutes Hyperalgesia - Companies Involved in Therapeutics Development Shionogi & Co., Ltd. Hyperalgesia - Therapeutics Assessment Drug Profiles LASSBio-873 - Drug Profile Drug For Neuropathic Pain - Drug Profile Drug For Methylglyoxal Induced Pains - Drug Profile P2X3 Receptor Antagonist - Drug Profile Protein Kinase 1 Alpha Inhibitor - Drug Profile Selective Phospholipase A2 Inhibitors - Drug Profile Hyperalgesia - Dormant Projects Companies Mentioned Shionogi & Co., Ltd. For more information visit http://www.researchandmarkets.com/research/rr...peralgesia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Rhabdomyosarcoma - Pipeline Review, H2 2013 Includes Players such as Eli Lilly and Company and Neotropix, Inc.
M2 - Wed Jan 22, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/s85dzx/rhabdomyosarcoma) has announced the addition of the "Rhabdomyosarcoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Rhabdomyosarcoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Rhabdomyosarcoma. - A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rhabdomyosarcoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Arisaph Pharmaceuticals, Inc. -Celgene Corporation -Daiichi Sankyo Company, Limited -Eli Lilly and Company -Merrimack Pharmaceuticals, Inc. -Neotropix, Inc. -Shionogi & Co., Ltd. -Vaccinex, Inc. For more information visit http://www.researchandmarkets.com/research/s8...myosarcoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Report on the International High-Growth Diagnostic Testing Markets
M2 - Mon Jan 13, 7:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3946g5/highgrowth) has announced the addition of the "2013 Report on the International High-Growth Diagnostic Testing Markets" report to their offering. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. This examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned: - A Menarini Diagnostics - Bayer Corporation - Calypte Biomedical Corporation - Denka Seiken - EY Laboratories - Enterix - Genetix - Genzyme Diagnostics - Hologic Gen Probe - Instrumentation Laboratory - Jiangnan Biotech - Johnson & Johnson - Kyowa Medex - LifeAssays AB - LifeScan - Matritech - NOVA Biomedical - OraSure - Pheromone Sciences Corporation - QIAGEN NV - Radiometer Medical - Roche Diagnostics - Shanghai SIIC Kehua Biotech - Shionogi & Co - Siemens Healthcare Diagnostics - Spectral Diagnostics - Trinity Biotech - V?samed - diaDexus For more information visit http://www.researchandmarkets.com/research/3946g5/highgrowth
Sezary Syndrome Global Clinical Trials Review, H2 2013 - Features Players such as Merck & Co., Inc. and Shionogi & Co., Ltd.
M2 - Fri Jan 10, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/l3xgrw/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Sezary Syndrome Global Clinical Trials Review, H2, 2013" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Angimmune LLC -Eisai Co., Ltd. -Emergent BioSolutions Inc. -Janssen Global Services, LLC -Kirin Holdings Company, Limited -Merck & Co., Inc. -National Cancer Institute -Northwestern University -OncoSec Medical Inc. -Roswell Park Cancer Institute -Shionogi & Co., Ltd. -Spectrum Pharmaceuticals, Inc. -Stanford University -University of Washington -Wake Forest University For more information visit http://www.researchandmarkets.com/research/l3...y_syndrome About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Respiratory Tract Infections - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/665vfh/respiratory_tract) has announced the addition of the "Respiratory Tract Infections - Pipeline Review, H2 2013" report to their offering. The report provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for Respiratory Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Infections. Scope - A snapshot of the global therapeutic scenario for Respiratory Tract Infections. - A review of the Respiratory Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Respiratory Tract Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Respiratory Tract Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Respiratory Tract Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Afexa Life Sciences - Cubist Pharmaceuticals - Daiichi Sankyo - Dongwha Pharm - GlaxoSmithKline - iBio. - Johnson & Johnson - Nanotherapeutics - Nippon Shinyaku - Novabiotics - Shionogi & Co. - Taisho Pharmaceutical For more information visit http://www.researchandmarkets.com/research/66...tory_tract About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Research Report: Osteosarcoma - Pipeline Review, H2 2013
M2 - Wed Nov 27, 2:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/pdllxv/osteosarcoma) has announced the addition of the "Osteosarcoma - Pipeline Review, H2 2013" report to their offering. 'Osteosarcoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteosarcoma. Scope - A snapshot of the global therapeutic scenario for Osteosarcoma. - A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteosarcoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Osteosarcoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Merck & Co., Inc. Oncolytics Biotech Inc. Med Discovery SA Aileron Therapeutics, Inc. Hawthorn Pharmaceuticals, Inc. Eleison Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/pd...teosarcoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Age Related Macular Degeneration - Pipeline Review, H2 2013
M2 - Thu Nov 21, 3:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/qks7tx/age_related) has announced the addition of the "Age Related Macular Degeneration - Pipeline Review, H2 2013" report to their offering. 'Age Related Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Age Related Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration. Scope - A snapshot of the global therapeutic scenario for Age Related Macular Degeneration. - A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Age Related Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. Johnson & Johnson F. Hoffmann-La Roche Ltd. Allergan, Inc. Shionogi & Co., Ltd. Lux Biosciences, Inc. RetinaPharma Technologies, Inc. Jeil Pharmaceutical Co., Ltd. Merz GmbH & Co. KGaA BioDiem Ltd ReGenX Biosciences, LLC OXiGENE, Inc. Zenotech Laboratories Limited NeoStem, Inc. Progen Pharmaceuticals Limited and many more... For more information visit http://www.researchandmarkets.com/research/qk...ge_related About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sarcomas - Pipeline Review, H2 2013
M2 - Thu Nov 07, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/t2h6sz/sarcomas) has announced the addition of the "Sarcomas - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Sarcomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcomas. Scope - A snapshot of the global therapeutic scenario for Sarcomas. - A review of the Sarcomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Sarcomas pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Sarcomas. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Sarcomas pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - AstraZeneca - Axelar - Eisai - Eli Lilly and Company - Gamida Cell - GlaxoSmithKline - MabVax Therapeutics - Marshall Edwards - Morphotek - Neotropix - Oncolytics Biotech - PCI Biotech - Pharmacyclics - Philogen - Polaris Group - Shionogi & Co. For more information visit http://www.researchandmarkets.com/research/t2h6sz/sarcomas About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Squamous Cell Carcinoma - Pipeline Review, H2 2013
M2 - Wed Nov 06, 3:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/fnth8k/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma. Scope - A snapshot of the global therapeutic scenario for Squamous Cell Carcinoma. - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Squamous Cell Carcinoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Boehringer Ingelheim - Cannabis Science - Cellceutix - Clinuvel Pharmaceuticals - Eli Lilly and Company - GENEXTRA - Genmab - GlaxoSmithKline - IRX Therapeutics - Merrimack Pharmaceuticals - NexMed - Novartis - Omeros - Oncolytics Biotech - Oryzon - Shionogi & Co. For more information visit http://www.researchandmarkets.com/research/fn...amous_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pruritus - Pipeline Review, H2 2013
M2 - Tue Nov 05, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/x8lqsw/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Pruritus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pruritus. Scope - A snapshot of the global therapeutic scenario for Pruritus. - A review of the Pruritus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pruritus pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Pruritus. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Cara Therapeutics - ELORAC - GlaxoSmithKline - Johnson & Johnson - Nippon Shinyaku - Shionogi & Co. - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/x8lqsw/pruritus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Perennial Allergic Rhinitis - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c3s2sh/perennial) has announced the addition of the "Perennial Allergic Rhinitis - Pipeline Review, H2 2013" report to their offering. 'Perennial Allergic Rhinitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Perennial Allergic Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis. Scope - A snapshot of the global therapeutic scenario for Perennial Allergic Rhinitis. - A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Perennial Allergic Rhinitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. GlaxoSmithKline plc Pfizer Inc. Teva Pharmaceutical Industries Limited GenMont Biotech Inc. VentiRx Pharmaceuticals, Inc. Adamis Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/c3s2sh/perennial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Obesity - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8nk97f/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2013" report to their offering. 'Obesity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. Scope - A snapshot of the global therapeutic scenario for Obesity. - A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Obesity pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Boehringer Ingelheim GmbH Shionogi & Co., Ltd. Amgen Inc. Sanofi-Aventis AstraZeneca PLC Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Merck & Co., Inc. Novo Nordisk A/S Takeda Pharmaceutical Company Limited Plexxikon Inc. BioLineRx, Ltd. Ipsen S.A. Chong Kun Dang Pharmaceutical Glenmark Pharmaceuticals Ltd. GTx, Inc. Kissei Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Corporation Norgine Limited and much more... For more information visit http://www.researchandmarkets.com/research/8nk97f/obesity About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Thrombocytopenia - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/67bv4h/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H2 2013" report to their offering. 'Thrombocytopenia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thrombocytopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocytopenia. Scope - A snapshot of the global therapeutic scenario for Thrombocytopenia. - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thrombocytopenia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Thrombocytopenia Overview Therapeutics Development An Overview of Pipeline Products for Thrombocytopenia Thrombocytopenia Therapeutics under Development by Companies Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Pre-Clinical Stage Products Comparative Analysis Thrombocytopenia Therapeutics - Products under Development by Companies Appendix Methodology List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. GlaxoSmithKline plc BioLineRx, Ltd. Eisai Co., Ltd. Octapharma AG Ono Pharmaceutical Co., Ltd. Cleveland BioLabs, Inc. Portola Pharmaceuticals, Inc. Uni-Bio Science Group Ltd. Cellerant Therapeutics, Inc. Pharmagenesis, Inc. Bolder Biotechnology, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/67...ocytopenia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Urinary Tract Infections - Pipeline Review, H2 2013
M2 - Thu Sep 05, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q89r4h/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2013" report to their offering. 'Urinary Tract Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Tract Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections.Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Urinary Tract Infections Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Toyama Chemical Co. Ltd - Paratek Pharmaceuticals, Inc. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Plethora Solutions Holdings plc - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - ConjuGon, Inc. - Osel Inc. - Pinnacle Pharmaceuticals, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/q8...nary_tract
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Neuropathic Pain - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fcxlmd/neuropathic_pain) has announced the addition of the "Neuropathic Pain - Pipeline Review, H2 2013" report to their offering. 'Neuropathic Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathic Pain. Scope - A snapshot of the global therapeutic scenario for Neuropathic Pain. - A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuropathic Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Genzyme Corporation DURECT Corporation Kyowa Hakko Kirin Co., Ltd. Biogen Idec Inc. Allergan, Inc. Shionogi & Co., Ltd. Sanofi-Aventis AstraZeneca PLC BioDelivery Sciences International, Inc. Nektar Therapeutics MedImmune LLC Quark Pharmaceuticals, Inc. Daiichi Sankyo Company, Ltd Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Sangamo BioSciences, Inc. XenoPort, Inc. BioLineRx, Ltd. Samyang Corporation Acorda Therapeutics, Inc. Astellas Pharma Inc. and many more... For more information visit http://www.researchandmarkets.com/research/fc...athic_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Allergic Rhinitis - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7llmpg/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2013" report to their offering. 'Allergic Rhinitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhinitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhinitis. - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Rhinitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. Boehringer Ingelheim GmbH Bausch & Lomb Incorporated Shionogi & Co., Ltd. GlaxoSmithKline plc Genentech, Inc. Nektar Therapeutics Dainippon Sumitomo Pharma Co., Ltd. Novartis AG ALK-Abello A/S Glenmark Pharmaceuticals Ltd. Mitsubishi Tanabe Pharma Corporation Ono Pharmaceutical Co., Ltd. Pfizer Inc. Teva Pharmaceutical Industries Limited Zeria Pharmaceutical Co Ltd Sun Pharmaceutical Industries Limited Revance Therapeutics, Inc. FAES Farma SA Nuvo Research Inc. Hisamitsu Pharmaceutical Co., Inc. Array BioPharma Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7l...c_rhinitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.